title: Comparison of a silicon carbide-coated stent versus a noncoated stent in human beings: the Tenax versus Nir Stent Study's long-term outcome.
abstract: BACKGROUND
  Stents coated with amorphous hypothrombogenic silicon carbide (a-SiC:H) have low restenosis rates in humans. Recurrence in a-SiC:H at mid-term follow-up has been shown to be similar to a stainless steel device. The long-term outcome, however, may be different.
  
  
  METHODS
  Four hundred ninety-seven patients (63.4 +/- 9.8 years of age) received either the a-SiC:H-coated Tenax stent (Biotronik, Berlin, Germany) or the 316L Nir stent (Boston Scientific, Maple Grove, Minn). Lesions had to be covered with one stent only (diameter > or =2.8 mm, length <20 mm). Exclusion criteria comprised acute myocardial infarction and angiographic thrombus within the target vessel. Twenty-five of 497 (5%) patients were excluded for protocol violation. Clinical follow-up was completed in 450 of 472 (95.3%) and angiographic follow-up was completed in 365 of 472 (77.3%); 22 of 472 (4.7%) patients were lost to follow-up.
  
  
  RESULTS
  Major adverse coronary events occurred in 28 of 233 (12%) of the Tenax recipients and in 31 of 217 (14.3%) of the Nir recipients (P =.50). Acute myocardial infarctions were less frequent in the Tenax recipients after > or =60 weeks. Premature target lesion revascularization was performed in 16 of 233 (6.9%) patients in the Tenax group and 11 of 217 (5.1%) (P =.54) patients in the Nir group. Coronary bypass operations were similar after Tenax or Nir stent deployment (3/233 [1.3%] vs 6/217 [2.8%], P =.43), as were deaths in 7 of 233 (3%) versus 8 of 217 (3.7%) (P =.88), respectively.
  
  
  CONCLUSIONS
  Both stents had a low rate of major adverse coronary events at 81 +/- 12 weeks of follow-up, with no definite superiority of any of the devices.
authors.affiliation: Center for Cardiovascular Diseases, Rotenburg an der Fulda, Germany. camus.hkz.rotenburg@t-online.de
authors.forename: Martin
authors.initials: M
authors.lastname: Unverdorben
authors.forename: Babett
authors.initials: B
authors.lastname: Sippel
authors.forename: Ralf
authors.initials: R
authors.lastname: Degenhardt
authors.forename: Katherine
authors.initials: K
authors.lastname: Sattler
authors.forename: Roland
authors.initials: R
authors.lastname: Fries
authors.forename: Bernd
authors.initials: B
authors.lastname: Abt
authors.forename: Eberhard
authors.initials: E
authors.lastname: Wagner
authors.forename: Henning
authors.initials: H
authors.lastname: Koehler
authors.forename: Gabriele
authors.initials: G
authors.lastname: Daemgen
authors.forename: Manfred
authors.initials: M
authors.lastname: Scholz
authors.forename: Hassan
authors.initials: H
authors.lastname: Ibrahim
authors.forename: Karl-Heinz
authors.initials: KH
authors.lastname: Tews
authors.forename: Benno
authors.initials: B
authors.lastname: Hennen
authors.forename: Heiner K
authors.initials: HK
authors.lastname: Berthold
authors.forename: Christian
authors.initials: C
authors.lastname: Vallbracht
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation*; D017554:Carbon Compounds, Inorganic; D002985:Clinical Protocols; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D004867:Equipment Design; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012008:Recurrence; D017655:Silicon Compounds; D015607:Stents / Q000592:standards*
chemical_list: D017554:Carbon Compounds, Inorganic; D017655:Silicon Compounds; C022088:silicon carbide